STOCK TITAN

Lipocine (LPCN) 10-K Filings

LPCN NASDAQ

Here are the 10-K annual reports from Lipocine Inc. (LPCN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow LPCN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LPCN filings page.

Rhea-AI Summary

Lipocine Inc. is a clinical-stage biopharmaceutical company using a proprietary oral lipid-based delivery platform to improve absorption of hard‑to‑deliver drugs, with a focus on CNS disorders, liver disease, and hormone therapies.

The company has transformed its testosterone replacement therapy franchise into a licensing model. Verity holds exclusive rights to TLANDO in the U.S. and Canada, paying Lipocine $2.5 million on signing, $5 million in February 2024, $2.5 million in December 2024 and $1 million in January 2026, plus up to $259 million in potential milestones and tiered royalties of 12%–18%. Additional TLANDO licenses cover South Korea (SPC), Gulf Cooperation Council countries (Pharmalink) and Brazil (Aché), each with upfront fees, milestones and supply arrangements.

Lipocine’s lead CNS asset, LPCN 1154 for postpartum depression, has completed enrollment and last patient visit in a Phase 3 trial, with data expected in April 2026 to support a planned 505(b)(2) NDA. Other neuroactive steroid programs target major depressive disorder, epilepsy and essential tremor. In liver disease, LPCN 1148 showed Phase 2 proof‑of‑concept in decompensated cirrhosis with improved muscle mass and fewer decompensation events. Research and development spending was $8.6 million in 2025 versus $7.4 million in 2024. As of March 9, 2026, Lipocine had 7,299,687 common shares outstanding and reported a $16.4 million aggregate market value of non‑affiliate holdings as of June 30, 2025.